Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals

• Published in: Urology journal Vol. 11; no. 6; pp. 1952 - 1958
• Main Authors: Moradi Sardareh, Hemen, Goodarzi, Mohammad Taghi, Yadegar-Azari, Reza, Poorolajal, Jalal, Mousavi-Bahar, Seyed Habibollah, Saidijam, Massoud
• Format: Journal Article
• Language: English
• Published: Iran Urology and Nephrology Research Center 30.11.2014
• Subjects: Age Factors; Aged; Aged, 80 and over; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Biomarkers, Tumor - urine; Body Mass Index; Case-Control Studies; Diagnosis, Differential; Gene Expression Profiling; Humans; Iran; Male; Middle Aged; Prostate-Specific Antigen - blood; Prostate-Specific Antigen - genetics; Prostate-Specific Antigen - urine; Prostatic Hyperplasia - blood; Prostatic Hyperplasia - diagnosis; Prostatic Hyperplasia - urine; Prostatic Neoplasms - blood; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - urine; Sensitivity and Specificity; Iran
• ISSN: 1735-1308; 1735-546X

To determine the expression of prostate cancer antigen 3 (PCA3) gene in peripheral blood and urine sediments from patients with prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and normal subjects. A total number of 48 patients [24 with biopsy proven prostate cancer (PCa) and 24 with benign prostate hyperplasia (BPH)] were studied. Twenty-four healthy individuals were also recruited as control group. After blood and urine sampling, total RNA was extracted and cDNA was synthesized. Expression of PCA3 gene was assessed by quantitative reverse transcription polymerase chain reaction. Comparison of PCA3 gene expression between control and BPH groups indicated no statistically significant differences in both urine and blood samples. Patients with PCa demonstrated an increased PCA3 gene expression rate compared to control and BPH groups (10.64 and 7.17 folds, respectively). The rate of fold increased PCA3 gene expression in urine was 20.90, 20.90, and 20.35 in patients with PCa, BPH and normal subjects, respectively. Evaluation of PCA3 gene expression can be considered as a reliable marker for detection of PCa. Increased level of this marker in urine sediments is more sensitive than blood for distinguishing between cancerous and non-cancerous groups.